Since both the MAPK/ERK and PI3K/AKT signaling pathways converge into mTORC1, this signaling pathway may be crucial for the efficacy of targeted therapy in patients with BRAF-mutant melanoma. This evidence concerns the gene AKT1 and melanoma.